NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyMood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
About This Grant
The purpose of this Notice of Funding Opportunity (NOFO) is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.
Grant Summary
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) is a National Institutes of Health grant providing funding that varies by award for school district, small business, municipality. Applications are due 2028-01-07 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
How to Apply
Up to $0K
2028-01-07
- 1Confirm your organization is eligible for Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional): Frequently Asked Questions
Who is eligible for the Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)?
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) is offered by National Institutes of Health and is generally open to school district, small business, municipality, nonprofit, university, tribal government. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) provide?
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) provides an amount that varies by award per award from National Institutes of Health. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) deadline?
Applications for Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) are due 2028-01-07 (open). Because deadlines can change, verify the date with the funder, National Institutes of Health, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)?
To apply for Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional), confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.